After Cutting Back And Clinging On, Will Biotech Bounce Back In 2023?

Tough Conditions Will Persist In 2023

 
• By Andrew McConaghie

Industry investors foresee continued hardship for public companies still without compelling clinical data for their assets, plus the growing influence of the US Inflation Reduction Act on biopharma strategy.

Biotech
Around 85% of companies which IPO'd in 2020 and 2021 are currently below their initial market values, reflecting a harsher environment. • Source: Shutterstock

More from Business

More from Scrip